Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha-Interferon in hematological malignancies.

F J Giles1, H Ozer

  • 1Division of Medical Oncology, School of Medicine, University of North Carolina, Chapel Hill 27599-7305.

Current Opinion in Biotechnology
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

ESMO open·2025
Same author

Could immune cells be associated with nephropathy in Fabry disease patients?

International urology and nephrology·2023
Same author

Diagnostic value of MDCT in determining the perinephric fat tissue and renal sinus invasion in patients with clear cell renal cell carcinoma.

Nigerian journal of clinical practice·2021
Same author

Colonic fibronectin and E-cadherin in mild ulcerative colitis.

Bratislavske lekarske listy·2021
Same author

Relationships between hypoxia induced factor-1α and <sup>18</sup>F-FDG PET/CT parameters in colorectal cancer.

Revista espanola de medicina nuclear e imagen molecular·2019
Same author

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

JCO precision oncology·2019
Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026
Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026
Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026
Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026
Same journal

Harvesting insights from recent advances in yeast genomics for predictable and precision wine fermentation.

Current opinion in biotechnology·2026
Same journal

Minimal enzyme cascades for the aromatic-to-aromatic upgrading of lignin monomers.

Current opinion in biotechnology·2026
See all related articles

Alpha-interferon therapy shows significant clinical activity in six hematological malignancies. These include chronic myeloid leukaemia and hairy cell leukaemia, demonstrating broad efficacy.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Hematological malignancies represent a diverse group of cancers affecting blood, bone marrow, and lymph nodes.
  • Alpha-interferon (IFN-α) is a cytokine with known immunomodulatory and antiproliferative effects.

Purpose of the Study:

  • To summarize recent data on the clinical activity of alpha-interferon therapy.
  • To evaluate the efficacy of alpha-interferon across multiple hematological malignancies.

Main Methods:

  • Review of recent clinical studies and data generation.
  • Analysis of treatment outcomes in patients with specific hematological cancers.

Main Results:

  • Significant clinical activity observed with alpha-interferon therapy.

Related Experiment Videos

  • Demonstrated efficacy in chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphomas, multiple myelomatosis, and hairy cell leukaemia.

    • Conclusions:

    • Alpha-interferon is an effective therapeutic option for a range of hematological malignancies.
    • These findings support the continued use and investigation of alpha-interferon in hematologic oncology.